Chad's health minister has pressed private pharmaceutical wholesalers to comply with existing rules, activate authorised establishments and improve price transparency. The 16 November meeting also addressed supplies to public health facilities, according to Le N'Djam Post. For foreign medicine suppliers, the immediate issue is the regulated distribution channel through which their products reach the country.1
The report summarised the ministry's priority as:
respect strict de la réglementation pharmaceutique
strict compliance with pharmaceutical regulation.1
Wholesalers asked for stronger involvement by relevant public services in applying professional rules and harmonising prices. A pharmacists' representative proposed further talks with the regulator and professional organisations. The meeting therefore records concerns on both sides; it does not announce a newly enacted import prohibition.1
Authorisation follows the medicine through distribution
The existing framework includes a decree signed on 14 August 2015, reproduced by Légitchad as in force. It requires health-ministry authorisation for wholesale establishments and their branches, alongside professional conditions for ownership or management. A responsible pharmacist oversees the operation.2
Crucially for cross-border purchasing, orders for imported pharmaceutical products require a prior import visa from the pharmaceutical regulator. Wholesalers may distribute only authorised products and must verify that their customers are legally entitled to receive them. Direct sales to the public are prohibited. The decree also requires appropriate storage and transport and a recall procedure.2
Those requirements distinguish a commercial order from permission to supply the market. An overseas producer's agreement with a distributor cannot, by itself, replace the establishment, product and import controls described in the decree.2
Cooperation is not automatic market access
An October report by Ecomnews Med, drawing on Ecofin, described a pharmaceutical and medical-device memorandum signed by Egypt and Chad. The agreement concerns regulatory and technical cooperation, information exchange and the quality and safety of products. Chad's health ministry had announced the agreement on 4 October.3
Such cooperation could help authorities and businesses navigate different regulatory systems. However, the reported memorandum does not establish automatic recognition of Egyptian products, dispense with Chad's import requirements or demonstrate new shipment volumes. Its commercial significance will depend on the arrangements that follow, rather than the signature alone.3
Chad is also discussing domestic production. In its reporting on an international pharmaceutical forum in N'Djamena, Manara described official calls to develop local manufacturing and reduce dependence on foreign suppliers. Speakers linked the ambition to fragile supply chains and the fight against falsified medicines. These were policy objectives, not evidence that a new factory had entered commercial operation.4
Taken together, the production discussion raises a separate question from the November compliance meeting: whether future investment can expand the supply of locally made products while meeting quality requirements. For now, the forum account offers no operating-output measure against which to judge that ambition. Concrete manufacturing projects and their regulatory approvals would provide the next useful test of progress.4